![Avizohar Argov](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Avizohar Argov
Corporate Officer/Principal bij The Hebrew University Hadassah Medical School
Actieve functies van Avizohar Argov
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
The Hebrew University Hadassah Medical School | Corporate Officer/Principal | - | - |
Loopbaan van Avizohar Argov
Eerdere bekende functies van Avizohar Argov
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Bioblast Pharma Ltd.
![]() Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Hoofd Techniek/Wetenschap/O&O | 01-06-2014 | - |
Statistieken
Internationaal
Israël | 3 |
Operationeel
Chief Tech/Sci/R&D Officer | 1 |
Corporate Officer/Principal | 1 |
Sectoraal
Health Technology | 2 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Bioblast Pharma Ltd.
![]() Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Health Technology |
- Beurs
- Insiders
- Avizohar Argov
- Ervaring